Payment overview · 2025
General Payments
$130.97
6 reported records · 4 companies
Healthcare provider profile · identity verified
David Alan Palmore, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FRESNO, CA · NPI 1619977444
Verified facts
What the public records show
CMS Open Payments records show David Alan Palmore, M.D. received $130.97 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 51.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.38 | 51.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.61 | 24.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.89 | 12.1% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $15.09 | 11.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $130.97 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.39 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.61 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $15.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 530 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 526 | 147 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 513 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 122 |
| Metformin Hcl | Metformin Hcl | 352 | 114 |
| Lisinopril | Lisinopril | 327 | 91 |
| Losartan Potassium | Losartan Potassium | 311 | 98 |
| Omeprazole | Omeprazole | 226 | 74 |
| Tramadol Hcl | Tramadol Hcl | 213 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 62 |
| Gabapentin | Gabapentin | 184 | 53 |
| Alprazolam | Alprazolam | 183 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 57 |
| Simvastatin | Simvastatin | 150 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 74 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 25 |
| Potassium Chloride | Potassium Chloride | 132 | 46 |
| Furosemide | Furosemide | 121 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 37 |
| Ozempic | Semaglutide | 102 | 26 |
| Carvedilol | Carvedilol | 101 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 33 |
| Ibuprofen | Ibuprofen | 97 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 97 | 12 |
| Jardiance | Empagliflozin | 96 | 33 |
| Ezetimibe | Ezetimibe | 92 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 22 |
| Azithromycin | Azithromycin | 86 | 71 |
| Clonazepam | Clonazepam | 85 | 12 |
| Allopurinol | Allopurinol | 81 | 29 |
| Trazodone Hcl | Trazodone Hcl | 80 | 20 |
| Lorazepam | Lorazepam | 73 | 16 |
| Baclofen | Baclofen | 72 | 24 |
| Farxiga | Dapagliflozin Propanediol | 71 | 29 |
| Lovastatin | Lovastatin | 68 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 19 |
| Benazepril Hcl | Benazepril Hcl | 64 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 53 |
| Diazepam | Diazepam | 60 | 15 |
| Atenolol | Atenolol | 59 | 14 |
| Finasteride | Finasteride | 57 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 17 |
| Eliquis | Apixaban | 46 | 11 |
| Temazepam | Temazepam | 46 | suppressed |
| Meloxicam | Meloxicam | 45 | 17 |
| Azelastine Hcl | Azelastine Hcl | 44 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 14 |
| Metformin Hcl Er | Metformin Hcl | 44 | 18 |
| Montelukast Sodium | Montelukast Sodium | 44 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 33 |
| Glipizide | Glipizide | 40 | 13 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Valsartan | Valsartan | 40 | 15 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Famotidine | Famotidine | 37 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 13 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 12 |
| Mupirocin | Mupirocin | 35 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | 11 |
| Fenofibrate | Fenofibrate | 34 | 11 |
| Fluconazole | Fluconazole | 34 | 21 |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 14 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Estradiol | Estradiol | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 13 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 15 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 17 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 14 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Primidone | Primidone | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130.97 · 6 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Ozempic, PREVNAR 20, Quviviq | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error